1.
Transpl Infect Dis
; 13(2): 117-21, 2011 Apr.
Artigo
em Inglês
| MEDLINE
| ID: mdl-20804534
RESUMO
A total of 26 adults with hematologic malignancies and/or hematopoietic stem cell transplant were treated for respiratory syncytial virus (RSV) infection based on an institutional guideline. Thirteen patients received aerosolized ribavirin, and 13 received aerosolized ribavirin and intravenous palivizumab. Two deaths, not attributed to RSV infection, occurred within 90 days of diagnosis.